MedPath

Association of Beta Blocker Use with Depressive Outcomes

Not yet recruiting
Conditions
Depression - Major Depressive Disorder
Registration Number
NCT06743633
Lead Sponsor
Chitkara University
Brief Summary

An Observational Study to Explore the Association Between β-Blocker Use and Depressive Outcomes

Detailed Description

Study design- This is a Prospective, Retrospective, Cross-sectional observational study. In prospective study, cardiovascular patients will be divided into two groups: those taking β-blockers and those not taking β-blockers. A questionnaire-based study will be conducted to assess the depression status of both groups. The study will include Depression Inventory (MDI) (lCD-10), Hamilton Rating Scale for Depression (HDRS) and Patient health questionnaire-9 (PHQ-9) for prospective study.

In the Retrospective study, clinically diagnosed depression patients with cardiovascular co morbidity will be identified from the psychiatric department.

Study population- Total number of patients to be included in both prospective and retrospective study: 1136 Prospective: 684 participants from cardiology department (two subgroups = 342 with β-blockers and other 342 without β-blockers) Retrospective: 452 participants from psychiatric department (two subgroups = 226 with β-blockers and other 226 without β-blockers) Planned time period for the study: Jan 2025 to May 2025 Procedure- Prospective: A prospective study, a total of 684 cardiovascular participants will be recruited from the Cardiology department. Participants will be divided into two groups: participants who are currently on β-blockers from at least 1 year and those who are not on β-blockers. Then a Depression Inventory (MDI) (lCD-10), Hamilton Rating Scale for Depression (HDRS) and PHQ-9 (Patient health questionnaire-9) depression questionnaire will be run on both to assess depression levels. Data collected from both groups will be compared to evaluate differences in depression status.

Retrospective: A retrospective study will be conducted involving 452 patients diagnosed with depression and atleast one cardiovascular co morbidity from the psychiatry department. Patients will be classified into two groups: those who were prescribed with β-blockers and those who were not. Medical records of these patients will be obtained from their respective Staff. The primary objective is to determine the prevalence of β-blocker use among depressed patients with cardiovascular conditions by reviewing their medical histories.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
1136
Inclusion Criteria
  1. Participants aged from ≥18 years at the time of consent.
  2. Participants on β-blockers for at least 1 year.
  3. No significant cognitive impairment.
  4. Participants who are willing to participate.
  5. To be able to understand and answer the self-assessment questionnaires.
Exclusion Criteria
  1. Having severe sensory and physical limitations, severe disconnection from the environment, or presence of severe neuropsychiatric symptoms that make it impossible to administer the assessment.

For Retrospective Study:-

Inclusion criteria:

  1. Diagnosis with major depressive disorder or reference to "clinical depression" in patient charts.
  2. Participants with cardiovascular co-morbidity.
  3. Participants aged from ≥18 years.

Exclusion criteria:

  1. Depression with other psychiatric illness for e.g., schizophrenia, cognitive impairment and without any cardiac comorbidity.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
An Observational Study to Explore the Association Between β-Blocker Use and Depressive Outcomes6 months

β-blockers use are associated with antidepressant effect or not

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath